JulesLeonardDienstagMD

Hepatology & Liver Transplantation

Carl W. Walter Professor of Medicine, Harvard Medical School

Dr. Dienstag is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Mass General Hospital, 55 Fruit St
Gastrointestinal Unit, Jackson 7
Boston, MA 02114
Phone+1 617-726-7450

Fax+1 617-643-0446

Massachusetts General HospitalFellowship, Gastroenterology, 1976 - 1978
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of HealthFellowship, Research Associate, Hepatitis Virus Section, 1974 - 1976
University of ChicagoResidency, Internal Medicine, 1972 - 1974
Columbia University Vagelos College of Physicians and SurgeonsClass of 1972
Columbia CollegeA.B., Magna Cum Laude, 1964 - 1968

Distinguished Achievement Award American Association for the Study of Liver Diseases, 2014
Fellow American Association for the Advancement of Science, 2014
Fellow American Association for the Study of Liver Diseases, 2014
Fellow American Gastroenterological Association, 2006
Fellow American College of Physicians, 1979
Join now to see all

PubMed

4 citations
The Harvard Medical School Pathways curriculum: A comprehensive curricular evaluation.
Amy M Sullivan, Edward Krupat, Jules L Dienstag, Jakob I McSparron, Stephen R Pelletier
Medical Teacher. 2022-11-01
1 citations
Advanced Integrated Science Courses: Building a Skill Set to Engage With the Interface of Research and Medicine.
Eli M Miloslavsky, Henrike C Besche, Stephen B Calderwood, Bernard S Chang, Jules L Dienstag
Academic Medicine. 2022-10-01
4 citations
The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence
Marc G. Ghany, Anna S.F. Lok, Jules L. Dienstag, Stephen M. Feinstone, Jay H. Hoofnagle
Hepatology. 2021-11-01

Clinical Trial: The Hepatitis C Antiviral Long-Term Treatment Against CirrhosisNational Center For Research Resources2008
The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (Halt-C) TrialNational Center For Research Resources2004–2007
PEG Interferon Alpha + Ribavirin For Chronic Hepatitis CNational Center For Research Resources2000–2002
Peg-Inf VS Intron A For Patients With Chronic Hepatitis C Naive To InterferonNational Center For Research Resources1998–2002
Hepatitis C Clinical Trial-Clinical CentersNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2000
Intron A VS Intron A PLUS Ribavirin At 2 Doses To Treat Chronic Hepatitis CNational Center For Research Resources1998–2000
Intron A Monotherapy VS Intron A+ Ribavirin For Treatment Of Chronic Hepatitis CNational Center For Research Resources1997–2000
Phase I/II In Chronic Hepatitis C Patients, Failed Conventional TherapyNational Center For Research Resources1996–1999
Lamivudine VS Placebo In Chronic Hepatitis B Treatment Naive PatientsNational Center For Research Resources1996–1999
Recomb Interferon Beta Therapy In PTS W/ Chronic Hepatitis B &C--Dose RangingNational Center For Research Resources1997
Wellferon And Intron A For Treatment Of Chronic Hepatitis CNational Center For Research Resources1996–1997
Efficacy/Safety Of 24 &48 Weeks Of De-Escalating Regiman Of Roferon-ANational Center For Research Resources1996–1997